Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Esophageal Cancer Publications

Following is a cumulative list of Hoosier Cancer Research Network publications in esophageal cancer.

Manuscripts and Journal Articles

  • Beccera C, Hanna N, McCollum A, Bechar N, Timmerman R, DiMaio M, Kesler K, Yu M, Yan T, Choy H. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GEJ junction carcinomas: Hoosier Oncology Group GI05-92. J Thorac Oncol 2013 Nov;8(11):1425-9. doi: 10.1097/JTO.0b013e3182a46c3b PMID: 24084441
  • Jordan M. Schmitt, Scott R. Sommers, William Fisher, Rafat Ansari, Erwin Robin, Karuna Koneru, John McClean, Ziyue Liu, Nasser Hanna: Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group: GI06-112. J Thorac Oncol, 2012; 7: 760-763
  • Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Supplement Oncology News International, October 2003.

Abstracts, Posters, and Presentations

  • J. M. Schmitt, S. R. Sommers, W. Fisher, R. Ansari, E. Robin, K. Koneru, J. McClean, Z. Liu, N. Hanna. Sunitinib plus Paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group: GI06-112. Accepted as abstract at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr e14661)
  • A.K. Agarwala, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, M. Yu, Y. Tong, C.R. Beccera, H.Choy. Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group (HOG) and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL J Clin Oncol 27:15s, 2009 (suppl; abstr 4557)
  • M. M. Sgroi, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, Z. Hammoud, M. Yu, H. Choy, C. Beccera. Pre-Operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas-Southwestern: GI05-92. Accepted to the general poster session at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL
  • R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Hoosier Oncology Group GI00-16. Accepted to the general poster session at the ASCO annual meeting June 5-8, 2004, New Orleans, LA.
  • Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI00-16. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL